Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Potential Pharmacologic Targets for the Prevention of Rheumatoid Arthritis.

Isaacs JD, Iqbal K.

Clin Ther. 2019 May 16. pii: S0149-2918(19)30184-5. doi: 10.1016/j.clinthera.2019.04.020. [Epub ahead of print]

PMID:
31196649
2.

Keratinocyte growth factor impairs human thymic recovery from lymphopenia.

Coles AJ, Azzopardi L, Kousin-Ezewu O, Mullay HK, Thompson SA, Jarvis L, Davies J, Howlett S, Rainbow D, Babar J, Sadler TJ, Brown JWL, Needham E, May K, Georgieva ZG, Handel AE, Maio S, Deadman M, Rota I, Holländer G, Dawson S, Jayne D, Seggewiss-Bernhardt R, Douek DC, Isaacs JD, Jones JL.

JCI Insight. 2019 May 7;5. pii: 125377. doi: 10.1172/jci.insight.125377.

3.

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.

Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL Jr, Kimberly RP, Okada Y, van Riel PLC, Wolbink G, van der Horst-Bruinsma IE, de Vries N, Tak PP, Ohmura K, Canhão H, Guchelaar HJ, Huizinga TW, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P.

Ann Rheum Dis. 2019 Apr 29. pii: annrheumdis-2018-214877. doi: 10.1136/annrheumdis-2018-214877. [Epub ahead of print]

4.

White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities.

Alber J, Alladi S, Bae HJ, Barton DA, Beckett LA, Bell JM, Berman SE, Biessels GJ, Black SE, Bos I, Bowman GL, Brai E, Brickman AM, Callahan BL, Corriveau RA, Fossati S, Gottesman RF, Gustafson DR, Hachinski V, Hayden KM, Helman AM, Hughes TM, Isaacs JD, Jefferson AL, Johnson SC, Kapasi A, Kern S, Kwon JC, Kukolja J, Lee A, Lockhart SN, Murray A, Osborn KE, Power MC, Price BR, Rhodius-Meester HFM, Rondeau JA, Rosen AC, Rosene DL, Schneider JA, Scholtzova H, Shaaban CE, Silva NCBS, Snyder HM, Swardfager W, Troen AM, van Veluw SJ, Vemuri P, Wallin A, Wellington C, Wilcock DM, Xie SX, Hainsworth AH.

Alzheimers Dement (N Y). 2019 Apr 9;5:107-117. doi: 10.1016/j.trci.2019.02.001. eCollection 2019. Review.

5.

The London memory service audit and quality improvement programme.

Cook LD, Nichol KE, Isaacs JD.

BJPsych Bull. 2019 Mar 22:1-6. doi: 10.1192/bjb.2019.18. [Epub ahead of print]

6.

Routine musculoskeletal ultrasound findings impact diagnostic decisions maximally in autoantibody-seronegative early arthritis patients.

Iqbal K, Lendrem DW, Hargreaves B, Isaacs JD, Thompson B, Pratt AG.

Rheumatology (Oxford). 2019 Feb 8. doi: 10.1093/rheumatology/kez008. [Epub ahead of print]

PMID:
30753709
7.

Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis.

Anderson AE, Maney NJ, Nair N, Lendrem DW, Skelton AJ, Diboll J, Brown PM, Smith GR, Carmody RJ, Barton A, Isaacs JD, Pratt AG.

Rheumatology (Oxford). 2019 Feb 8. doi: 10.1093/rheumatology/kez003. [Epub ahead of print]

PMID:
30753680
8.

Macrophage proliferation distinguishes 2 subgroups of knee osteoarthritis patients.

Wood MJ, Leckenby A, Reynolds G, Spiering R, Pratt AG, Rankin KS, Isaacs JD, Haniffa MA, Milling S, Hilkens CM.

JCI Insight. 2019 Jan 24;4(2). pii: 125325. doi: 10.1172/jci.insight.125325. [Epub ahead of print]

9.

Tolerising cellular therapies: what is their promise for autoimmune disease?

Mosanya CH, Isaacs JD.

Ann Rheum Dis. 2019 Mar;78(3):297-310. doi: 10.1136/annrheumdis-2018-214024. Epub 2018 Nov 2.

10.

Therapeutic tolerance in autoimmune disease.

Rayner F, Isaacs JD.

Semin Arthritis Rheum. 2018 Dec;48(3):558-562. doi: 10.1016/j.semarthrit.2018.09.008. Epub 2018 Sep 28. Review.

PMID:
30348449
11.

Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.

Ritchie CW, Russ TC, Banerjee S, Barber B, Boaden A, Fox NC, Holmes C, Isaacs JD, Leroi I, Lovestone S, Norton M, O'Brien J, Pearson J, Perry R, Pickett J, Waldman AD, Wong WL, Rossor MN, Burns A.

Alzheimers Res Ther. 2018 Jul 30;10(1):73. doi: 10.1186/s13195-018-0372-0.

12.

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, Isaacs JD, Hyrich KL; BSRBR-RA Contributors Group.

Ann Rheum Dis. 2018 Oct;77(10):1405-1412. doi: 10.1136/annrheumdis-2018-213378. Epub 2018 Jul 6.

13.

Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug Naïve Rheumatoid Arthritis.

Cooles FAH, Anderson AE, Skelton A, Pratt AG, Kurowska-Stolarska MS, McInnes I, Hilkens CMU, Isaacs JD.

Front Immunol. 2018 May 9;9:755. doi: 10.3389/fimmu.2018.00755. eCollection 2018.

14.

Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients.

Taylor JC, Bongartz T, Massey J, Mifsud B, Spiliopoulou A, Scott IC, Wang J, Morgan M, Plant D, Colombo M, Orchard P, Twigg S, McInnes IB, Porter D, Freeston JE, Nam JL, Cordell HJ, Isaacs JD, Strathdee JL, Arnett D, de Hair MJH, Tak PP, Aslibekyan S, van Vollenhoven RF, Padyukov L, Bridges SL, Pitzalis C, Cope AP, Verstappen SMM, Emery P, Barnes MR, Agakov F, McKeigue P, Mushiroda T, Kubo M, Weinshilboum R, Barton A, Morgan AW, Barrett JH; MATURA; and PAMERA; Consortia.

Pharmacogenomics J. 2018 Jul;18(4):528-538. doi: 10.1038/s41397-018-0025-5. Epub 2018 May 25. Review.

15.

A unifying theory for cognitive abnormalities in functional neurological disorders, fibromyalgia and chronic fatigue syndrome: systematic review.

Teodoro T, Edwards MJ, Isaacs JD.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1308-1319. doi: 10.1136/jnnp-2017-317823. Epub 2018 May 7. Review.

16.

Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaboration.

Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulze-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium.

Nat Rev Rheumatol. 2018 Jan 24;14(2):119. doi: 10.1038/nrrheum.2018.6.

PMID:
29362468
17.

The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review.

Pauls MM, Moynihan B, Barrick TR, Kruuse C, Madigan JB, Hainsworth AH, Isaacs JD.

J Cereb Blood Flow Metab. 2018 Feb;38(2):189-203. doi: 10.1177/0271678X17747177. Epub 2017 Dec 19.

18.

Corrigendum: Synovial tissue research: a state-of-the-art review.

Orr C, Vieira-Sousa E, Boyle DL, Buch MH, Buckley CD, Cañete JD, Catrina AI, Choy EHS, Emery P, Fearon U, Filer A, Gerlag D, Humby F, Isaacs JD, Just SA, Lauwerys BR, Goff BL, Manzo A, McGarry T, McInnes IB, Najm A, Pitzalis C, Pratt A, Smith M, Tak PP, Tas SW, Thurlings R, Fonseca JE, Veale DJ.

Nat Rev Rheumatol. 2017 Dec 19;14(1):60. doi: 10.1038/nrrheum.2017.206.

PMID:
29255214
19.

The RA-MAP Consortium: a working model for academia-industry collaboration.

Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulz-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium.

Nat Rev Rheumatol. 2018 Jan;14(1):53-60. doi: 10.1038/nrrheum.2017.200. Epub 2017 Dec 7. Review. Erratum in: Nat Rev Rheumatol. 2018 Jan 24;14 (2):119.

20.

CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis: Implications for Causal Gene Identification.

Thalayasingam N, Nair N, Skelton AJ, Massey J, Anderson AE, Clark AD, Diboll J, Lendrem DW, Reynard LN, Cordell HJ, Eyre S, Isaacs JD, Barton A, Pratt AG.

Arthritis Rheumatol. 2018 Mar;70(3):361-370. doi: 10.1002/art.40393. Epub 2018 Jan 30.

21.

The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.

Ritchie CW, Russ TC, Banerjee S, Barber B, Boaden A, Fox NC, Holmes C, Isaacs JD, Leroi I, Lovestone S, Norton M, O'Brien J, Pearson J, Perry R, Pickett J, Waldman AD, Wong WL, Rossor MN, Burns A.

Alzheimers Res Ther. 2017 Oct 26;9(1):85. doi: 10.1186/s13195-017-0312-4. Erratum in: Alzheimers Res Ther. 2018 Jul 30;10(1):73.

22.

The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy.

Cooles FAH, Anderson AE, Lendrem DW, Norris J, Pratt AG, Hilkens CMU, Isaacs JD.

J Allergy Clin Immunol. 2018 Jan;141(1):445-448.e4. doi: 10.1016/j.jaci.2017.08.026. Epub 2017 Oct 5. No abstract available.

23.

Synovial tissue research: a state-of-the-art review.

Orr C, Vieira-Sousa E, Boyle DL, Buch MH, Buckley CD, Cañete JD, Catrina AI, Choy EHS, Emery P, Fearon U, Filer A, Gerlag D, Humby F, Isaacs JD, Just SA, Lauwerys BR, Le Goff B, Manzo A, McGarry T, McInnes IB, Najm A, Pitzalis C, Pratt A, Smith M, Tak PP, Thurlings R, Fonseca JE, Veale DJ.

Nat Rev Rheumatol. 2017 Sep 22;13(10):630. doi: 10.1038/nrrheum.2017.161.

PMID:
28935945
24.

Targeting of tolerogenic dendritic cells towards heat-shock proteins: a novel therapeutic strategy for autoimmune diseases?

Jansen MAA, Spiering R, Broere F, van Laar JM, Isaacs JD, van Eden W, Hilkens CMU.

Immunology. 2018 Jan;153(1):51-59. doi: 10.1111/imm.12811. Epub 2017 Sep 18. Review.

25.
26.

Synovial tissue research: a state-of-the-art review.

Orr C, Vieira-Sousa E, Boyle DL, Buch MH, Buckley CD, Cañete JD, Catrina AI, Choy EHS, Emery P, Fearon U, Filer A, Gerlag D, Humby F, Isaacs JD, Just SA, Lauwerys BR, Le Goff B, Manzo A, McGarry T, McInnes IB, Najm A, Pitzalis C, Pratt A, Smith M, Tak PP, Thurlings R, Fonseca JE, Veale DJ, Tas SW.

Nat Rev Rheumatol. 2017 Aug;13(8):463-475. doi: 10.1038/nrrheum.2017.115. Epub 2017 Jul 13. Review. Erratum in: Nat Rev Rheumatol. 2017 Sep 22;13(10 ):630. Nat Rev Rheumatol. 2017 Dec 19;14 (1):60.

PMID:
28701760
27.

Non-hyperammonaemic valproate encephalopathy after 20 years of treatment.

Caruana Galizia E, Isaacs JD, Cock HR.

Epilepsy Behav Case Rep. 2017 Apr 21;8:9-11. doi: 10.1016/j.ebcr.2017.04.002. eCollection 2017.

28.

Traceless Cleavage of Protein-Biotin Conjugates under Biologically Compatible Conditions.

Cowell J, Buck M, Essa AH, Clarke R, Vollmer W, Vollmer D, Hilkens CM, Isaacs JD, Hall MJ, Gray J.

Chembiochem. 2017 Sep 5;18(17):1688-1691. doi: 10.1002/cbic.201700214. Epub 2017 Jul 19.

29.

Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease (PASTIS): study protocol for a randomised controlled trial.

Pauls MMH, Clarke N, Trippier S, Betteridge S, Howe FA, Khan U, Kruuse C, Madigan JB, Moynihan B, Pereira AC, Rolfe D, Rostrup E, Haig CE, Barrick TR, Isaacs JD, Hainsworth AH.

Trials. 2017 May 22;18(1):229. doi: 10.1186/s13063-017-1973-9.

30.

Translational models for vascular cognitive impairment: a review including larger species.

Hainsworth AH, Allan SM, Boltze J, Cunningham C, Farris C, Head E, Ihara M, Isaacs JD, Kalaria RN, Lesnik Oberstein SA, Moss MB, Nitzsche B, Rosenberg GA, Rutten JW, Salkovic-Petrisic M, Troen AM.

BMC Med. 2017 Jan 25;15(1):16. doi: 10.1186/s12916-017-0793-9. Review.

31.

The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort.

Smith SL, Plant D, Eyre S, Hyrich K, Morgan AW, Wilson AG, Isaacs JD, Barton A.

Rheumatology (Oxford). 2017 Jun 1;56(6):1019-1024. doi: 10.1093/rheumatology/kew387.

32.

Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies.

Cooles FA, Anderson AE, Drayton T, Harry RA, Diboll J, Munro L, Thalayasingham N, Östör AJ, Isaacs JD.

Arthritis Res Ther. 2016 Dec 20;18(1):302.

33.

Patient and researcher perspectives on facilitating patient and public involvement in rheumatology research.

Pollock J, Raza K, Pratt AG, Hanson H, Siebert S, Filer A, Isaacs JD, Buckley CD, McInnes IB, Falahee M.

Musculoskeletal Care. 2017 Dec;15(4):395-399. doi: 10.1002/msc.1171. Epub 2016 Dec 16. No abstract available.

34.

Let's not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect!

Baker KF, Pratt AG, Thompson B, Isaacs JD.

Ann Rheum Dis. 2017 Jun;76(6):e12. doi: 10.1136/annrheumdis-2016-210797. Epub 2016 Dec 1. No abstract available.

PMID:
27934680
35.

Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers.

Brown PM, Pratt AG, Isaacs JD.

Nat Rev Rheumatol. 2016 Dec;12(12):731-742. doi: 10.1038/nrrheum.2016.175. Epub 2016 Oct 27. Review.

PMID:
27784891
36.

Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T cells partly via transforming growth factor-β1.

Anderson AE, Swan DJ, Wong OY, Buck M, Eltherington O, Harry RA, Patterson AM, Pratt AG, Reynolds G, Doran JP, Kirby JA, Isaacs JD, Hilkens CM.

Clin Exp Immunol. 2017 Jan;187(1):113-123. doi: 10.1111/cei.12870. Epub 2016 Nov 2.

37.

Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23.

McGovern A, Schoenfelder S, Martin P, Massey J, Duffus K, Plant D, Yarwood A, Pratt AG, Anderson AE, Isaacs JD, Diboll J, Thalayasingam N, Ospelt C, Barton A, Worthington J, Fraser P, Eyre S, Orozco G.

Genome Biol. 2016 Nov 1;17(1):212.

38.

Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies.

Lord P, Spiering R, Aguillon JC, Anderson AE, Appel S, Benitez-Ribas D, Ten Brinke A, Broere F, Cools N, Cuturi MC, Diboll J, Geissler EK, Giannoukakis N, Gregori S, van Ham SM, Lattimer S, Marshall L, Harry RA, Hutchinson JA, Isaacs JD, Joosten I, van Kooten C, Lopez Diaz de Cerio A, Nikolic T, Oral HB, Sofronic-Milosavljevic L, Ritter T, Riquelme P, Thomson AW, Trucco M, Vives-Pi M, Martinez-Caceres EM, Hilkens CMU.

PeerJ. 2016 Aug 30;4:e2300. doi: 10.7717/peerj.2300. eCollection 2016.

39.

Clinical trials of biosimilars should become more similar.

Kay J, Isaacs JD.

Ann Rheum Dis. 2017 Jan;76(1):4-6. doi: 10.1136/annrheumdis-2015-208113. Epub 2016 Aug 25. No abstract available.

PMID:
27566795
40.

Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels.

Jani M, Isaacs JD, Morgan AW, Wilson AG, Plant D, Hyrich KL, Chinoy H, Barton A.

Rheumatology (Oxford). 2016 Nov;55(11):2050-2055. Epub 2016 Aug 25.

41.

Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data.

Pratt AG, Lendrem D, Hargreaves B, Aslam O, Galloway JB, Isaacs JD.

Rheumatology (Oxford). 2016 Oct;55(10):1843-8. doi: 10.1093/rheumatology/kew261. Epub 2016 Jul 3.

42.

Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.

Clowse ME, Feldman SR, Isaacs JD, Kimball AB, Strand V, Warren RB, Xibillé D, Chen Y, Frazier D, Geier J, Proulx J, Marren A.

Drug Saf. 2016 Aug;39(8):755-62. doi: 10.1007/s40264-016-0431-z.

43.

High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.

Jani M, Isaacs JD, Morgan AW, Wilson AG, Plant D, Hyrich KL, Chinoy H, Barton A; BRAGGSS.

Ann Rheum Dis. 2017 Jan;76(1):208-213. doi: 10.1136/annrheumdis-2015-208849. Epub 2016 May 31.

44.

Drug breakthrough offers hope to arthritis sufferers: qualitative analysis of medical research in UK newspapers.

Hanson H, O'Brien N, Whybrow P, Isaacs JD, Rapley T.

Health Expect. 2017 Apr;20(2):309-320. doi: 10.1111/hex.12460. Epub 2016 May 4.

45.

Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis.

Bell GM, Anderson AE, Diboll J, Reece R, Eltherington O, Harry RA, Fouweather T, MacDonald C, Chadwick T, McColl E, Dunn J, Dickinson AM, Hilkens CM, Isaacs JD.

Ann Rheum Dis. 2017 Jan;76(1):227-234. doi: 10.1136/annrheumdis-2015-208456. Epub 2016 Apr 26.

46.

Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis.

Plant D, Webster A, Nair N, Oliver J, Smith SL, Eyre S, Hyrich KL, Wilson AG, Morgan AW, Isaacs JD, Worthington J, Barton A.

Arthritis Rheumatol. 2016 Jun;68(6):1353-60. doi: 10.1002/art.39590. Epub 2016 Apr 21.

47.

Cytokines in rheumatoid arthritis - shaping the immunological landscape.

McInnes IB, Buckley CD, Isaacs JD.

Nat Rev Rheumatol. 2016 Jan;12(1):63-8. doi: 10.1038/nrrheum.2015.171. Epub 2015 Dec 10. Review.

PMID:
26656659
48.

Bcl-3 in CD4+ T Cell-Mediated Rheumatoid Arthritis Pathogenesis: Comment on the Article by Meguro et al.

Pratt AG, Anderson AE, Carmody RJ, Isaacs JD.

Arthritis Rheumatol. 2016 Mar;68(3):770-1. doi: 10.1002/art.39509. No abstract available.

49.

Teaching examples for the design of experiments: geographical sensitivity and the self-fulfilling prophecy.

Lendrem DW, Lendrem BC, Rowland-Jones R, D'Agostino F, Linsley M, Owen MR, Isaacs JD.

Pharm Stat. 2016 Jan-Feb;15(1):90-2. doi: 10.1002/pst.1723. Epub 2015 Nov 12.

PMID:
26559516
50.

Lost in space: design of experiments and scientific exploration in a Hogarth Universe.

Lendrem DW, Lendrem BC, Woods D, Rowland-Jones R, Burke M, Chatfield M, Isaacs JD, Owen MR.

Drug Discov Today. 2015 Nov;20(11):1365-71. doi: 10.1016/j.drudis.2015.09.015. Epub 2015 Oct 23. Review.

PMID:
26505134

Supplemental Content

Loading ...
Support Center